Topotecan

Near the separatrix ~3 mm mapped to outer mid-plane ; and a broader base profile elsewhere in the scrape-off-layer ~5-7 mm-omp ; . Without gas puffing, the narrow layer was found to scale inversely with power entering the SOL, q, nw PSOL-0.4 0.1, while the base profile showed virtually no power dependence. At constant input power 12 MW ; , the peak heat flux was strongly reduced by D2 puffing from ~ 20 to with the narrow feature in the power profile effectively suppressed. Comparison of the total power profile from TC analysis ; with the electron power profile from Langmuir probes LP ; , allowed the calculation of the ion power profile. Decomposition into the ion and electron channels, and into the double exponential thin-wide ; components, revealed a strong correspondence of the narrow layer with the ions, and of the base profile with the electrons, Figs.4-5 here parallel heat flux is shown, where q|| qtarget ~ 13 ; . The peak heat flux was dominated by the ions for PSOL 8 MW no gas puff ; and for D2 puff rate 1022 s-1 12 MW.

Prentis, R. A., Lis, Y. & Walker, S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies 19641985 ; . Br. J. Clin. Pharmacol. 25, 387396 1988 ; . 2. Venkatesh, S. & Lipper, R. A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89, 145154 2000 ; . 3. Schena, M., Shalon, D., Davis, R. W. & Brown, P. O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467470 1995 ; . 4. Lockhart, D. J. et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nature Biotechnol. 14, 16751680 1996 ; . 5. Lockhart, D. J. & Winzeler, E. A. Genomics, gene expression and DNA arrays. Nature 405, S827S836 2000 ; . 6. Hughes, T. R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109126 2000 ; . 7. Bartosiewicz, M., Penn, S. & Buckpitt, A. Applications of gene arrays in environmental toxicology: fingerprints of gene regulation associated with cadmium chloride, benzo a ; pyrene, and trichloroethylene. Environ. Health Perspect. 109, 7174 2001 ; . 8. Bartosiewicz, M. J., Jenkins, D., Penn, S., Emery, J. & Buckpitt, A. Unique gene expression patterns in liver and kidney associated with exposure to chemical toxicants. J. Pharmacol. Exp. Ther. 297, 895905 2001 ; . 9. Bulera, S. J. et al. RNA expression in the early characterization of hepatotoxicants in Wistar rats by highdensity DNA microarrays. Hepatology 33, 12391258 2001 ; . 10. Cunningham, M. J., Liang, S., Fuhrman, S., Seilhamer, J. J. & Somogyi, R. Gene expression microarray data analysis for toxicology profiling. Ann. NY Acad. Sci. 919, 5267 2000 ; . 11. Pennie, W. D., Woodyatt, N. J., Aldridge, T. C. & Orphanides, G. Application of genomics to the definition of the molecular basis for toxicity. Toxicol Lett. 31, 353358 2001 ; . 12. Reilly, T. P. et al. Expression profiling of acetaminophen liver toxicity in mice using microarray technology. Biochem. Biophys. Res. Commun. 282, 321328 2001 ; . 1. 13. Rockett, J. C. et al. Development of a 950-gene DNA array for examining gene expression patterns in mouse testis. Genome Biol. 2000 ; . [ : genomebiology 2001 2 4 research 0014 ] 14. Waring, J. et al. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175, 2842 2001 ; . 15. Burczynski, M. E. et al. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol. Sci. 58, 399415 2000 ; . 16. Waring, J. F., Ciurlionis, R., Jolly, R. A., Heindel, M. & Ulrich, R. G. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120, 359368 2001 ; . 17. Quackenbush, J. Computational analysis of microarray data. Nature Rev. Genet. 2, 418427 2001 ; . 18. Gupta, S., Husser, R. C., Geske, R. S., Welty, S. E. & Smith, C. V. Sex differences in diquat-induced hepatic necrosis and DNA fragmentation in Fischer 344 rats. Toxicol. Sci. 54, 203211 2000 ; . 19. Benigni, R. et al. Mutational studies with diquat and paraquat in vitro. Mutat. Res. 68, 183193 1979 ; . 20. Gasch, A. P. et al. Genomic expression responses to DNA-damaging agents and the regulatory role of the yeast ATR homolog Mec1p. Mol. Biol. Cell 12, 29873003 2001 ; . 21. Thomas, R. S. et al. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. 60, 11891194 2001 ; . 22. Waring, J. R. et al. Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor. Toxicology in the press ; . 23. Zielinski, N. P. et al. Expression profiling using DNA microarrays reveals a functional antagonism of the peroxisome proliferator activated receptor- by the protease inhibitor, ritonavir. Abstr. 41st Interscience Conference Antimicrob. Agents Chemother. 229, American Society for Microbiology, Washington, 2001 ; . 24. Gerhold, D. et al. Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol. Genomics 5, 161170 2001 ; . 25. Stratowa, C. et al. cDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int. J. Cancer 91, 474480 2001.

Results correlated closely with those of more invasive tests that have been reported in scientific literature. Study results showed that CFS patients had a lower cortisol response to awakening, indicative of HPA axis dysfunction. Several variables were considered in the study population, including comorbid depression vs. no depression, smokers vs. nonsmokers, medications vs. no medications, female vs. male, body mass index and awakening times. Test results were not statistically different between the groups. Some limitations of the trial included the relatively small size of the study group and the fact that the group consisted of patients who were recruited from a clinic population that may not be representative of the general population. The study was unable to ascertain if HPA axis changes cause CFS, or if they occur as a consequence of the illness. However, it did strengthen the findings of previous studies indicating that changes to the HPA axis may represent one of the biological factors that contribute to ongoing fatigue and CFS symptoms and tranylcypromine. Oral versus intravenous topotecan Gore and colleagues33 ; One publication of a single RCT that compared oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer met the inclusion criteria.33 and topotecan. The Advanced RN practitioner must be enrolled as a provider in order to bill for the provision of WV Medicaid services. Prescriptive authority is not required to be enrolled as a provider. An Advanced Nurse Practitioner must have a signed collaborative agreement for prescriptive authority with a physician who is enrolled with BMS. This collaborative agreement which must be on file at the BMS ; must document the professional relationship between the Advanced RN practitioner and the physician. The Advanced RN practitioner must notify BMS immediately, and if necessary submit a replacement document, if the collaborative agreement is cancelled, changed, or not renewed. 503.4 ENROLLMENT: GROUP PAY-TO PRACTICES Providers whose practice is incorporated under the same tax identification number or have an employeremployee relationship must enroll as a Medicaid group pay-to provider. To receive Medicaid payments, each provider employed by or directing payment to the group pay-to must be enrolled as an individual provider and designate that payment for rendered services is to be made to the group pay-to entity. Individuals can participate in multiple groups and all such relationships must be documented with provider enrollment in order that payments may be appropriately made to the correct entity and reported to the correct tax identification number. Termination of the corporation or the employer- employee relationship must be reported in writing, on office letterhead stationery, to the Provider Enrollment Unit. The notice must include the effective date of the termination. Failure to report these changes will result in incorrect routing of payments and invalid filings with the Internal Revenue Service. 503.5 ENROLLMENT: OTHER PRACTITIONERS Enrollment requirements of other practitioners, e.g. chiropractors, podiatrists, and therapists, are discussed in the Chapter 500 which corresponds to those specific providers. 503.6 ENROLLMENT: DOCUMENTATION Documentation including required license, certifications, proof of completion of training, contracts between physicians and physician assistants, collaborative agreements for prescriptive authority, if applicable, between certified nurse practitioners and physicians, and any other materials substantiating an individual's and treprostinil. The chemical structure and biological action of topotecan is similar to that of camptothecin and irinotecan.

In the past, the Cardassians were a peaceful and spiritual people. But because their planet was resource poor, starvation and disease were rampant and people died by the millions. With the rise of the military to power, new territories and technology were acquired through violence, at the cost of millions of lives sacrificed to the war effort. In Cardassian society, the criminal justice system served to enforce cultural norms, while reassuring the public with the comforting notion that good did triumph over evil. Accordingly, no criminal to trial until authorities had already found the defendant guilty. Trials were broadcast for viewing by the public, serving as a dramatic demonstration of the futility of violating society norms. Under the Cardassian system of jurisprudence, a defendant could not present evidence until the trial was under way In other words, until after a verdict of guilty had already been rendered. Further, such defendants were required to testify against themselves. Cardassian citizens were required to have one of their molars extracted at the age of 10 so that they could be kept on file by the Cardassian bureau of identification. In Cardassian culture, advanced age is viewed as a sign of power and dignity. Cardassian men and women sometimes exhibit overt irritability toward each other as an overture to a sexual relationship. Family is very important to the Cardassians, with some households being multi-generational. Intense mind training programs are given to their children as early as four years of age, perhaps contributing to the famous Cardassian photographic memories. Cardassian funeral rites are very strict. They consider it a dishonor to the diseased if a non-Cardassian views the remains. Cardassians dislike cold temperatures. It is traditional in Cardassian culture that the commanding officer of a ship entertains guests when they travel aboard his or her ship. A favorite morning beverage is hot fish juice and triac. 43. 44. 45. Rich, P. R., and Bendall, D. S. 1979 ; FEBS Lett. 105, 189 194 Nohl, H., Gille, L., and Kozlov, A. V. 1998 ; Free Radic. Biol. Med. 25, 666 675 Kaiser, J. 2003 ; Science 302, 376 379 Calabrese, E. J. 2004 ; EMBO Rep. 5, S37S40 Hsu, A. Y., Do, T. Q., Lee, P. T., and Clarke, C. F. 2000 ; Biochim. Biophys. Acta 1484, 287297 Diekert, K., de Kroon, A. I., Kispal, G., and Lill, R. 2001 ; Methods Cell Biol. 65, 3751 Murphy, M. P., Echtay, K. S., Blaikie, F. H., Asin-Cayuela, J., Cocheme, H. M., Green, K., Buckingham, J. A., Taylor, E. R., Hurrell, F., Hughes, G., Miwa, S., Cooper, C. E., Svistunenko, D. A., Smith, R. A., and Brand, M. D. 2003 ; J. Biol. Chem. 278, 48534 48545 Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. 1985 ; Anal. Biochem. 150, 76 85 Smith, A. L. 1967 ; Methods Enzymol. 10, 81 86 Walker, J. E., Skehel, J. M., and Buchanan, S. K. 1995 ; Methods Enzymol. 260, 14 34 Chappell, J. B., and Hansford, R. G. 1972 ; in Subcellular Components: Preparation and Fractionation Birnie, G. D., ed ; 2nd Ed., pp. 7791, Butterworths, London Gornall, A. G., Bardawill, C. J., and David, M. M. 1949 ; J. Biol. Chem. 177, 751766 James, A. M., Wei, Y. H., Pang, C. Y., and Murphy, M. P. 1996 ; Biochem. J. 318, 401 407 Garrib, A., and McMurray, W. C. 1986 ; J. Biol. Chem. 261, 8042 8048 Hughes, M. N., and Nicklin, H. G. 1968 ; J. Am. Chem. Soc. A, 450 452 Packer, M. A., and Murphy, M. P. 1994 ; FEBS Lett. 345, 237240 Rose, I. A., and O'Connell, E. L. 1967 ; J. Biol. Chem. 242, 1870 1879 Gardner, P. R. 2002 ; Methods Enzymol. 349, 9 23 Gralla, E. B., and Valentine, J. S. 1991 ; J. Bacteriol. 173, 5918 5920 Tyler, D. D. 1992 ; The Mitochondrion in Health and Disease, pp. 4193, VCH Publishers Inc., New York Yankovskaya, V., Horsefield, R., Tornroth, S., Luna-Chavez, C., Miyoshi, H., Leger, C., Byrne, B., Cecchini, G., and Iwata, S. 2003 ; Science 299, 700 704 Gao, X., Wen, X., Esser, L., Quinn, B., Yu, L., Yu, C. A., and Xia, D. 2003 ; Biochemistry 42, 90679080 Okada, K., Kainou, T., Matsuda, H., and Kawamukai, M. 1998 ; FEBS Lett. 431, 241244 Rich, P. R. 1984 ; Biochim. Biophys. Acta 768, 5379 Crane, F. L., and Barr, R. 1971 ; Methods Enzymol. C18, 137165 Takada, M., Ikenoya, S., Yuzuriha, T., and Katayama, K. 1984 ; Methods Enzymol. 105, 147155 Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., and Freeman, B. A. 1990 ; Proc. Natl. Acad. Sci. U. S. A. 87, 1620 1624 Schopfer, F., Riobo, N., Carreras, M. C., Alvarez, B., Radi, R., Boveris, A., Cadenas, E., and Poderoso, J. J. 2000 ; Biochem. J. 349, 35 42 Genova, M. L., Pich, M. M., Biondi, A., Bernacchia, A., Falasca, A., Bovina, C., Formiggini, G., Castelli, G. P., and Lenaz, G. 2003 ; Exp. Biol. Med. Maywood ; 228, 506 513 Rich, P. R., and Bendall, D. S. 1980 ; Biochim. Biophys. Acta 592, 506 518 Azzi, A., Montecucco, C., and Richter, C. 1975 ; Biochem. Biophys. Res. Commun. 65, 597 603 Winterbourn, C. C. 1981 ; Arch. Biochem. Biophys. 209, 159 167 Palmer, R. M., Ferrige, A. G., and Moncada, S. 1987 ; Nature 327, 524 526 Carreras, M. C., Franco, M. C., Peralta, J. G., and Poderoso, J. J. 2004 ; Mol. Aspects Med. 25, 125139 Nisoli, E., Falcone, S., Tonello, C., Cozzi, V., Palomba, L., Fiorani, M., Pisconti, A., Brunelli, S., Cardile, A., Francolini, M., Cantoni, O., Carruba, M. O., Moncada, S., and Clementi, E. 2004 ; Proc. Natl. Acad. Sci. U. S. A. 101, 1650716512 Brown, G. C. 2001 ; Biochim. Biophys. Acta 1504, 46 57 Liu, L., Yan, Y., Zeng, M., Zhang, J., Hanes, M. A., Ahearn, G., McMahon, T. J., Dickfeld, T., Marshall, H. E., Que, L. G., and Stamler, J. S. 2004 ; Cell 116, 617 628 Poderoso, J. J., Carreras, M. C., Schopfer, F., Lisdero, C. L., Riobo, N. A., Giulivi, C., Boveris, A. D., Boveris, A., and Cadenas, E. 1999 ; Free Radic. Biol. Med. 26, 925935 St-Pierre, J., Buckingham, J. A., Roebuck, S. J., and Brand, M. D. 2002 ; J. Biol. Chem. 277, 44784 44790 Lambert, A. J., and Brand, M. D. 2004 ; Biochem. J. 382, 511517 Crompton, M. 1999 ; Biochem. J. 341, 233249 Xia, D., Yu, C. A., Kim, H., Xia, J. Z., Kachurin, A. M., Zhang, L., Yu, L., and Deisenhofer, J. 1997 ; Science 277, 60 66 Santos-Ocana, C., Do, T. Q., Padilla, S., Navas, P., and Clarke, C. F. 2002 ; J. Biol. Chem. 277, 1097310981 Aure, K., Benoist, J. F., Ogier de Baulny, H., Romero, N. B., Rigal, O., and Lombes, A. 2004 ; Neurology 63, 727729 Dallner, G., and Sindelar, P. J. 2000 ; Free Radic. Biol. Med. 29, 285294 Gillis, J. C., Benefield, P., and McTavish, D. 1994 ; Drugs Aging 5, 133152 Rustin, P., von Kleist-Retzow, J. C., Chantrel-Groussard, K., Sidi, D., Munnich, A., and Rotig, A. 1999 ; Lancet 354, 477 479 Buyse, G., Mertens, L., Di Salvo, G., Matthijs, I., Weidemann, F., Eyskens, B., Goossens, W., Goemans, N., Sutherland, G. R., and Van Hove, J. L. 2003 ; Neurology 60, 1679 1681 Yokoo, S., Furumoto, K., Hiyama, E., and Miwa, N. 2004 ; J. Cell. Biochem. 93, 588 597 Meyer, M., Schreck, R., and Baeuerle, P. A. 1993 ; EMBO J. 12, 20052015 Borrello, S., and Demple, B. 1997 ; Arch. Biochem. Biophys. 348, 289 294 Muller, J. M., Rupec, R. A., and Baeuerle, P. A. 1997 ; Methods 11, 301312 Petersen, D. R., and Doorn, J. A. 2004 ; Free Radic. Biol. Med. 37, 937945 and toradol. It and its close chemical relatives aminocamptothecin, cpt-11 , dx-8951f, and topotecan ; are the only known naturally-occurring dna topoisomerase i inhibitors and triazolam.
Topoisomerase I inhibitor. Daily administration of topotecan inhibited HIF-1a expression, angiogenesis, and growth of glioma xenografts 10 ; , thus providing a rationale for an ongoing clinical trial of topotecan in patients with cancers that have been shown to overexpress HIF-1a by immunohistochemistry. A second screening assay for compounds that inhibit HIF-1 DNA binding activity in vitro led to the identification of echinomycin as a novel inhibitor of HIF-1-dependent transcription 11 ; . Echinomycin binds to the DNA sequence 5V -ACGT-3V which is present in a , subset of binding sites recognized by HIF-1 5V -ACGTG-3V and ; C-MYC 5V -CACGTG-3V ; . D. Del Bufalo Regina Elena Cancer Institute, Rome, Italy ; extended recent observations by her lab that Bcl2 overexpression increases vascular endothelial growth factor VEGF ; via HIF1-dependent transcription by reporting that Bcl2 overexpression stimulated the phosphorylation of AKT and extracellular signalregulated kinase 1 2 ERK1 2 ; proteins under hypoxic conditions, whereas Bcl2 had no effect on these proteins under nonhypoxic conditions. Bcl2 RNA interference decreased ERK1 2 phosphorylation and VEGF secretion in hypoxic Bcl2-overexpressing cells but not in control cells 12 ; . Thus, Bcl2 overexpression and hypoxia have synergistic effects on HIF-1-dependent gene expression in tumor cells. Finally, P. Burke EntreMed, Inc., Rockville, MD ; reported that.